Anika Therapeutics, Inc. (ANIK)
$12.92
-0.41 (-2.97%)Delayed quote.
Price history
Daily close- Start
- $9.65
- Latest close
- $12.92
- Period change
- +33.89%
- Period low
- $9.13
- Period high
- $22.03
Key metrics
- Market cap
- $179.50M
- Volume
- 87.8K
- Average volume
- 104.6K
- 52-week range
- $7.87 – $22.88
- Beta
- 0.21
- Last dividend
- —
- EPS (TTM)
- -$0.13
- P/E ratio
- -12.64
- Revenue (TTM)
- $123.43M
- Net income (TTM)
- -$1.77M
- Total assets
- $189.60M
- Total debt
- $24.57M
- Cash and equivalents
- $44.96M
Key financials (trailing twelve months).
Company profile
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Exchange
- NASDAQ
- CEO
- Stephen D. Griffin
- Employees
- 235
- Headquarters
- Bedford, MA, US
- IPO date
- 1993-05-03
- Website
- https://www.anika.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Revenue | $112.82M | $119.91M | $120.79M |
| Gross profit | $63.81M | $76.00M | $82.53M |
| Operating income | -$11.05M | -$5.10M | $844.0K |
| EBITDA | -$3.58M | $5.36M | $17.37M |
| Net income | -$10.88M | -$56.38M | -$82.67M |
| Diluted EPS | -$0.76 | -$3.83 | -$5.64 |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $57.48M | $55.63M | $68.74M |
| Total assets | $190.27M | $202.74M | $270.63M |
| Total liabilities | $46.80M | $48.75M | $58.37M |
| Total debt | $26.25M | $25.93M | $27.74M |
| Shareholders’ equity | $143.47M | $153.99M | $212.26M |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | $11.19M | $5.40M | -$1.79M |
| Capital expenditure | -$6.83M | -$7.73M | -$5.43M |
| Free cash flow | $4.36M | -$2.33M | -$7.21M |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $30.59M | $32.61M | $29.61M | $30.61M | $27.82M | $28.22M |
| Gross profit | $18.84M | $21.24M | $19.00M | $19.18M | $15.58M | $14.36M |
| Operating income | -$712.0K | $2.95M | -$5.49M | $646.0K | -$3.23M | -$4.18M |
| EBITDA | $1.58M | $4.88M | -$3.41M | $2.08M | -$833.0K | -$2.55M |
| Net income | -$311.0K | $3.31M | -$5.06M | $292.0K | -$2.33M | -$3.97M |
| Diluted EPS | -$0.02 | $0.24 | -$0.37 | $0.02 | -$0.16 | -$0.28 |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $44.96M | $38.41M | $41.02M | $57.48M | $57.99M | $53.17M |
| Total assets | $189.60M | $183.47M | $179.39M | $190.27M | $189.44M | $187.68M |
| Total liabilities | $52.02M | $46.19M | $45.49M | $46.80M | $42.63M | $40.01M |
| Total debt | $24.57M | $23.32M | $25.74M | $26.25M | $24.51M | $24.99M |
| Shareholders’ equity | $137.58M | $137.28M | $133.90M | $143.47M | $146.81M | $147.67M |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $8.38M | -$684.0K | -$4.85M | $4.64M | $6.87M | -$189.0K |
| Capital expenditure | -$1.66M | -$1.45M | -$1.43M | -$648.0K | -$1.89M | -$1.47M |
| Free cash flow | $6.72M | -$2.13M | -$6.28M | $3.99M | $4.98M | -$1.66M |